Gleiss Lutz has advised one of the participating investors on its investment in the biotechnology company BioNTech. The Series B financing round totalling USD 325 million was led by Fidelity Management & Research Company with participation from both new and existing investors, including Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management, the Struengmann Family Office and other European family offices. Two-thirds of the funding came from new investors.
BioNTech AG is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all of the building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing.
BioNTech will use the capital raised to support the continued advancement of its therapeutics pipeline and manufacturing infrastructure.
Gleiss Lutz already assisted the investor with BioNTech’s Series A financing round. The firm regularly advises investors in the area of venture capital and start-ups, including Tiger Global on an investment in the German start-up Flaschenpost, Naspers on the acquisition of a stake in the Frontier Car Group and Heinz Dürr Invest on ubitricity’s financing rounds.
The investor was advised by Dr. Martin Viciano Gofferje (partner, lead) and Dr. Micha Pfarr (both corporate/M&A, both Berlin).
Forward
